JMP Securities analyst David Turkaly lowered the firm’s price target on Integra LifeSciences to $65 from $75 and keeps an Outperform rating on the shares. Quarterly sales were slightly above the high end of the guidance range, while adjusted EPS was about in line with the midpoint, and management reiterated its annual guidance ranges on both the top and bottom lines, but also provided additional commentary around why 1H23 will be a bit softer than the back half of the year, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IART:
- Integra LifeSciences Reports First Quarter 2023 Financial Results
- Integra LifeSciences sees Q2 adjusted EPS 75c-79c, consensus 85c
- Integra LifeSciences backs FY23 adjusted EPS view $3.43-$3.51, consensus $3.48
- Integra LifeSciences reports Q1 adjusted EPS 74c, consensus 74c
- Integra LifeSciences price target raised to $62 from $58 at Truist